Phaseline

Companies › Urovant Sciences

Urovant Sciences: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 3; Neurology, Metabolic and endocrine; next expected readout Mar 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vibegron
Beta-3 adrenergic receptor agonist
ADRB3Phase 2Neurogenic Detrusor Overactivity; ObesityMar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06987383VibegronPhase 3ObesityMetabolic and endocrineJul 2028
NCT05491525VibegronPhase 2Neurogenic Detrusor OveractivityNeurologyMar 2030

Targets

ADRB3 (1)

Companies with the same targets

Astellas

Companies built like this

Shenzhen Wingor Biotechnology NeuroBiogen Corxel Pharmaceuticals PRG Science & Technology Actimed Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.